Literature DB >> 10976552

Thiopurine methyltransferase polymorphic tandem repeat: genotype-phenotype correlation analysis.

L Yan1, S Zhang, B Eiff, C L Szumlanski, M Powers, J F O'Brien, R M Weinshilboum.   

Abstract

BACKGROUND: Thiopurine methyltransferase (TPMT) is a genetically polymorphic enzyme that catalyzes the S-methylation of thiopurine drugs such as 6-mercaptopurine. Recently, a variable number tandem repeat (VNTR) within the TPMT promoter has been reported to "modulate" levels of this enzyme activity.
METHODS: We set out to perform genotype-phenotype correlation analysis for the polymorphic TPMT tandem repeat in 1211 clinical laboratory samples in which red blood cell (RBC) TPMT activity had been measured and to compare those results with data for 279 control DNA samples.
RESULTS: TPMT VNTR length varied from three to nine repeats ( *V3 to *V9), but the most common alleles were *V4 and *V5, with frequencies in the control samples of 0.54 and 0.36, respectively. The clinical laboratory samples were then stratified into those with "low," "intermediate," or "high" levels of RBC TPMT activity; that is, samples presumed to be homozygous for open reading frame (ORF)-based variant alleles, heterozygous for those alleles, or homozygous for the "wild-type" ORF sequence, respectively. TPMT VNTR genotype *V4/*V5 was associated with significantly higher RBC TPMT activity than were *V4/*V4 or *V5/*V5. Lowest activity levels were associated with genotypes that included an allele with more than 5 repeat elements. However, all of these effects were quantitatively small. Finally, there was linkage disequilibrium between VNTR allele *V5 and TPMT*3A, the most common ORF-based polymorphism associated with very low TPMT activity in white persons.
CONCLUSIONS: These observations suggest that, in addition to the striking effects of ORF-based single nucleotide polymorphisms on TPMT activity, the VNTR within the 5'-flanking region of the TPMT gene also may modulate levels of RBC TPMT activity.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10976552     DOI: 10.1067/mcp.2000.108674

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  22 in total

Review 1.  Pharmacogenomics: catechol O-methyltransferase to thiopurine S-methyltransferase.

Authors:  Richard M Weinshilboum
Journal:  Cell Mol Neurobiol       Date:  2006-06-29       Impact factor: 5.046

2.  Phenotyping and genotyping studies of thiopurine S-methyltransferase in Kazaks.

Authors:  Hong Wei; Shufeng Zhou; Chengrong Li; Jianping Zhang; Jueheng Wu; Min Huang
Journal:  Pharm Res       Date:  2005-09-22       Impact factor: 4.200

3.  Structural basis of allele variation of human thiopurine-S-methyltransferase.

Authors:  Hong Wu; John R Horton; Kevin Battaile; Abdellah Allali-Hassani; Fernando Martin; Hong Zeng; Peter Loppnau; Masoud Vedadi; Alexey Bochkarev; Alexander N Plotnikov; Xiaodong Cheng
Journal:  Proteins       Date:  2007-04-01

Review 4.  Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer.

Authors:  Tessa M Bosch; Irma Meijerman; Jos H Beijnen; Jan H M Schellens
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

5.  Association of thiopurine methyltransferase status with azathioprine side effects in Chinese patients with systemic lupus erythematosus.

Authors:  Dongying Chen; Fan Lian; Shiwen Yuan; Yixi Wang; Zhongping Zhan; Yujin Ye; Qian Qiu; Hanshi Xu; Liuqin Liang; Xiuyan Yang
Journal:  Clin Rheumatol       Date:  2013-12-10       Impact factor: 2.980

6.  Phenotyping and genotyping study of thiopurine S-methyltransferase in healthy Chinese children: a comparison of Han and Yao ethnic groups.

Authors:  Jian-ping Zhang; Yong-yuan Guan; Jue-heng Wu; An-long Xu; Shufeng Zhou; Min Huang
Journal:  Br J Clin Pharmacol       Date:  2004-08       Impact factor: 4.335

7.  Thiopurine S-methyltransferase pharmacogenetics: functional characterization of a novel rapidly degraded variant allozyme.

Authors:  Qiping Feng; Suda Vannaprasaht; Yi Peng; Susothorn Angsuthum; Yingyos Avihingsanon; Vivien C Yee; Wichittra Tassaneeyakul; Richard M Weinshilboum
Journal:  Biochem Pharmacol       Date:  2009-11-27       Impact factor: 5.858

8.  Relationships between thiopurine S-methyltransferase polymorphism and azathioprine-related adverse drug reactions in Chinese renal transplant recipients.

Authors:  Hua-Wen Xin; Hui Xiong; Xiao-Chun Wu; Qing Li; Lei Xiong; Ai-Rong Yu
Journal:  Eur J Clin Pharmacol       Date:  2008-12-02       Impact factor: 2.953

9.  Implementation of TPMT testing.

Authors:  Lynne Lennard
Journal:  Br J Clin Pharmacol       Date:  2014-04       Impact factor: 4.335

10.  Pharmacogenetics during standardised initiation of thiopurine treatment in inflammatory bowel disease.

Authors:  U Hindorf; M Lindqvist; C Peterson; P Söderkvist; M Ström; H Hjortswang; A Pousette; S Almer
Journal:  Gut       Date:  2006-03-16       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.